FDA rejects Amphastar’s nasal opioid overdose treatment
Amphastar Pharmaceuticals Inc said on Tuesday that the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose…
Read More...
Read More...
